Two More Brain-Infection Cases Emerge in Tysabri Patients
Posted Nov 17 2009 10:20pm
AMAZINGLY this makes the news, each time I consent to trying Tysabri and then it (in the past) scared me away from trying it. However, because again this seems to only be happening in Europe, I will and am convinced that I need to, soon begin Tysabri.. - Stuart Schlossman
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold byBiogen IdecInc. andElanPLC,the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since the drug's relaunch in July 2006; Tysabri was pulled from the U.S. market in 2005 because of PML concerns.
A Biogen spokeswoman said the Cambridge, Mass., biotech company is neither commenting on nor confirming the existence of additional cases as long as the PML rate is consistent with the rate of one-in-1,000 patients implied by the label. The new cases appear to be in line with the label's rate.
CLICK here to finish reading of these new PML cases
ByTHOMAS GRYTA
Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold byBiogen IdecInc. andElanPLC,the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since the drug's relaunch in July 2006; Tysabri was pulled from the U.S. market in 2005 because of PML concerns.
A Biogen spokeswoman said the Cambridge, Mass., biotech company is neither commenting on nor confirming the existence of additional cases as long as the PML rate is consistent with the rate of one-in-1,000 patients implied by the label. The new cases appear to be in line with the label's rate.
============================================